Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0N7JZ
|
||||
Former ID |
DIB012408
|
||||
Drug Name |
SAND-26
|
||||
Synonyms |
Begedina; CD26-targeting antibody (autoimmunity), ADIENNE
|
||||
Drug Type |
Antibody
|
||||
Company |
ADIENNE Pharma & Biotech
|
||||
Target and Pathway | |||||
Target(s) | Dipeptidyl peptidase IV | Target Info | [551687] | ||
KEGG Pathway | Protein digestion and absorption | ||||
NetPath Pathway | IL2 Signaling Pathway | ||||
TGF_beta_Receptor Signaling Pathway | |||||
References | |||||
Ref 525143 | ClinicalTrials.gov (NCT02411084) Study of BEGEDINA vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD. U.S. National Institutes of Health. | ||||
Ref 543248 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8691). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.